Related Experiment Video

Updated: Jul 23, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K

Double Guard Efficiency and Safety-Overcoming Resistance to Immunotherapy by Blocking or Stimulating Several Immune

Ewa Kalinka1, Kamila Wojas-Krawczyk2, Paweł Krawczyk2

  • 1Department of Oncology, Polish Mother's Memorial Hospital-Research Institute, 93-338 Łódź, Poland.

Cancers
|July 14, 2023
PubMed

Insights

Dual immunologic checkpoint blockade shows promise for overcoming resistance in non-small cell lung cancer (NSCLC) immunotherapy. This strategy combines inhibitors like CTLA-4 and PD-1 to improve treatment effectiveness for patients who don't respond initially.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Immunotherapy is a key treatment for non-small cell lung cancer (NSCLC).
  • A significant number of NSCLC patients exhibit primary or secondary resistance to immunotherapy.
  • Predictive tools for immunotherapy resistance are lacking, leading to treatment failures.

Purpose of the Study:

  • To review existing data on combination immunotherapy strategies for NSCLC.
  • To explore the mechanisms, efficacy, and safety of dual immunologic checkpoint blockade.
  • To identify potential therapeutic targets for overcoming immunotherapy resistance.

Main Methods:

  • Systematic review of published and available data on combination immunotherapies.
  • Analysis of dual immunologic checkpoint blockade combinations.
  • Discussion of various immune checkpoint inhibitors including CTLA-4, PD-1/PD-L1, TIGIT, LAG-3, TIM-3, LILRB2/ILT4, SIGLEC-15, CD137, ICOS, and OX40.

Main Results:

  • Dual immunologic checkpoint blockade presents a scientific approach to circumvent resistance mechanisms.
  • Combination therapies offer potential for effective salvage second-line treatment in NSCLC.
  • The review encompasses a broad range of dual blockade combinations and their clinical implications.

Conclusions:

  • Dual immunologic checkpoint blockade is a promising strategy to enhance immunotherapy efficacy in NSCLC.
  • Further research into specific combinations is warranted to optimize patient outcomes.
  • Addressing immunotherapy resistance through combination therapies is crucial for improving NSCLC treatment.
Keywords:
immune checkpointsimmunotherapynon-small cell lung cancerresistance

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

439
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
567
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K